Pharma BD Deal Intelligence

AstraZeneca PLC / Acerta Pharma

2015 · Acquisition/Merger · $4.0B · Complete

Announcement Sentiment

75

Strongly positive

Outcome Score

86

Worked — the deal delivered on its rationale.

AstraZeneca acquired 55% of Acerta Pharma for $4B for BTK inhibitor.

Key facts

Announced Dec 17, 2015
Closed Feb 01, 2016
Deal value $4.0B
Deal type Acquisition/Merger
Therapeutic area Oncology
Key assets acalabrutinib

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals